Browsing by author "Pawlyn, Charlotte"
Now showing items 1-20 of 37
-
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.
Cook, G; Royle, K-L; Pawlyn, C; Hockaday, A; Shah, V; et al. (ELSEVIER SCI LTD, 2019-03-01)BACKGROUND: Tolerability of treatments for multiple myeloma can depend on the characteristics of the patient being treated. We aimed to develop and validate a risk profile, using routinely collected data, that could predict ... -
A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.
Bødker, JS; Brøndum, RF; Schmitz, A; Schönherz, AA; Jespersen, DS; et al. (ELSEVIER, 2018-09-25)Despite the recent progress in treatment of multiple myeloma (MM), it is still an incurable malignant disease, and we are therefore in need of new risk stratification tools that can help us to understand the disease and ... -
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
Leleu, X; Martin, T; Weisel, K; Schjesvold, F; Iida, S; et al. (SPRINGER, 2022-08-09)CD38 is a transmembrane glycoprotein that functions both as a receptor and an ectoenzyme, playing key roles in the regulation of calcium signaling and migration of immune cells to tumor microenvironments. High expression ... -
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial.
Pawlyn, C; Cairns, D; Menzies, T; Jones, J; Jenner, M; et al. (FERRATA STORTI FOUNDATION, 2022-01-01)Autologous stem cell transplant (ASCT) remains standard of care for consolidation after induction therapy for eligible newly diagnosed myeloma patients. In recent clinical trials comparing ASCT to delayed ASCT, patients ... -
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Jackson, GH; Pawlyn, C; Cairns, DA; de Tute, RM; Hockaday, A; et al. (PUBLIC LIBRARY SCIENCE, 2021-01-01)BACKGROUND: Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral neuropathy than first-generation proteasome inhibitors, ... -
Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma.
Mian, H; Grant, SJ; Engelhardt, M; Pawlyn, C; Bringhen, S; et al. (ELSEVIER, 2020-06-01) -
Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.
Agbuduwe, C; Iqbal, G; Cairns, D; Menzies, T; Dunn, J; et al. (ELSEVIER, 2022-09-13)Immunoglobulin D (IgD) myeloma is a subtype often considered to have adverse features and inferior survival, but there is a paucity of data from large clinical studies. We compare the clinical characteristics and outcomes ... -
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Jones, JR; Weinhold, N; Ashby, C; Walker, BA; Wardell, C; et al. (FERRATA STORTI FOUNDATION, 2019-06-30)The emergence of treatment resistant sub-clones is a key feature of relapse in multiple myeloma. Therapeutic attempts to extend remission and prevent relapse include maximizing response and the use of maintenance therapy. ... -
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Bygrave, C; Pawlyn, C; Davies, F; Craig, Z; Cairns, D; et al. (WILEY, 2020-06-10)Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. ... -
Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.
Coulson, AB; Royle, K-L; Pawlyn, C; Cairns, DA; Hockaday, A; et al. (BMJ PUBLISHING GROUP, 2022-06-02)INTRODUCTION: Multiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population.Over the last 10 years, patient outcomes have improved. However, this ... -
HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.
Fok, JHL; Hedayat, S; Zhang, L; Aronson, LI; Mirabella, F; et al. (AMER ASSOC CANCER RESEARCH, 2018-05-15)Purpose: Myeloma is a plasma cell malignancy characterized by the overproduction of immunoglobulin, and is therefore susceptible to therapies targeting protein homeostasis. We hypothesized that heat shock factor 1 (HSF1) ... -
Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients.
Panopoulou, A; Easdale, S; Ethell, M; Nicholson, E; Potter, M; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2023-02-01)Refined prediction of early relapse following standard-of-care (SoC) autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) could inform real-world risk-stratified post-ASCT strategies. We ... -
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; et al. (FERRATA STORTI FOUNDATION, 2021-07-01)The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question in a large phase III randomized trial, Myeloma XI. Patients ... -
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; et al. (ELSEVIER SCIENCE INC, 2019-01-01)BACKGROUND: Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide ... -
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Pawlyn, C; Loehr, A; Ashby, C; Tytarenko, R; Deshpande, S; et al. (NATURE PUBLISHING GROUP, 2018-07-01)PARP inhibitors can induce synthetic lethality in tumors characterized by homologous recombination deficiency (HRD), which can be detected by evaluating genome-wide loss of heterozygosity (LOH). Multiple myeloma (MM) is a ... -
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.
Rasche, L; Angtuaco, E; McDonald, JE; Buros, A; Stein, C; et al. (AMER SOC HEMATOLOGY, 2017-07-06)18F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and diffusion-weighted magnetic resonance imaging with background signal suppression (DWIBS) are 2 powerful functional imaging modalities in the evaluation ... -
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
de Tute, RM; Pawlyn, C; Cairns, DA; Davies, FE; Menzies, T; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-09-01)PURPOSE: Minimal residual disease (MRD) can predict outcomes in patients with multiple myeloma, but limited data are available on the prognostic impact of MRD when assessed at serial time points in the context of maintenance ... -
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.
Jones, JR; Barber, A; Le Bihan, Y-V; Weinhold, N; Ashby, C; et al. (SPRINGERNATURE, 2021-10-01) -
Neutral tumor evolution in myeloma is associated with poor prognosis.
Johnson, DC; Lenive, O; Mitchell, J; Jackson, G; Owen, R; et al. (AMER SOC HEMATOLOGY, 2017-10-05)Recent studies suggest that the evolutionary history of a cancer is important in forecasting clinical outlook. To gain insight into the clonal dynamics of multiple myeloma (MM) and its possible influence on patient outcomes, ... -
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Jackson, GH; Pawlyn, C; Cairns, DA; Striha, A; Collett, C; et al. (WILEY, 2021-03-01)Second-generation immunomodulatory agents, such as lenalidomide, have a more favourable side-effect profile than the first-generation thalidomide, but their optimum combination and duration for patients with newly diagnosed ...